CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myeloproliferative neoplasms (MPNs).
  
  OVERVIEW OF ACTIVITY
  MPNs largely consist of 3 disease entities, all heralding from clonal disorders in which an initial molecular event results in excessive production of blood cells. Importantly, although essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) are clinically distinguishable based on laboratory and molecular parameters, they may represent a disease continuum whereby transformation from ET or PV to the more aggressive MF results in a homogenous pathologic entity with a uniformly poor prognosis. In contrast to the rather indolent natural history of untransformed ET and PV, primary MF or post-PV/ET, MF is a debilitating disease. Historically no FDA-approved therapy existed, but after the FDA approval of ruxolitinib in 2011 for intermediate- and high-risk MF, including primary MF, post-PV MF and post-ET MF, this agent has rapidly been adopted in clinical practice. Patient selection and dosing of ruxolitinib remain relevant topics of discussion and debate. Not surprisingly, JAK inhibitors have been and continue to be critically evaluated for patients with both PV and ET. Most notably, in December 2014, the US FDA approved ruxolitinib as treatment for patients with PV who have experienced an inadequate response to or are intolerant of hydroxyurea. To bridge the gap between research and patient care, this program features a joint discussion with 2 leading hematology-oncology clinical investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity will assist medical oncologists with the formulation of up-to-date clinical management strategies for patients with MPNs.
  
  LEARNING OBJECTIVES

  • Use an understanding of disease biology, including mutational status, to diagnose patients with primary MF, and effectively counsel patients with these disorders regarding their long-term prognosis.
  • Appraise the evidence-based therapeutic options for patients with MF, PV and ET, and develop clinical algorithms intended to enhance quality and quantity of life for patients with these diseases.
  • Recall the tolerability profile with ruxolitinib, and formulate a plan to manage the side effects to support quality of life and continuation of treatment.
  • Appraise available and emerging research data with the use of novel JAK inhibitors in the care of patients with MF, and prepare for their potential availability in clinical practice.
  • Appreciate the biologic rationale for and emerging data with the use of erythroid maturation agents alone or in combination with JAK2 inhibitors in the treatment of patients with anemia secondary to MF.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Professor Claire Harrison
  Clinical Director
  Guy’s and St Thomas’ NHS Foundation Trust
  London, United Kingdom
  
  Advisory Committee: AOP Orphan Pharmaceuticals AG, Celgene Corporation, CTI BioPharma Corp, Gilead Sciences Inc, Incyte Corporation, Novartis, Pfizer Inc, Roche Laboratories Inc; Consulting Agreements: Celgene Corporation, CTI BioPharma Corp, Novartis; Contracted Research and Speakers Bureau: Celgene Corporation, Novartis; Data and Safety Monitoring Board: Roche Laboratories Inc.
  
  John Mascarenhas, MD
  Director, Adult Leukemia Program and Leader
  Myeloproliferative Neoplasms Clinical Research Program
  Icahn School of Medicine at Mount Sinai
  New York, New York
  
  Advisory Committee: Constellation Pharmaceuticals, CTI BioPharma Corp, Incyte Corporation, Roche Laboratories Inc; Consulting Agreement: Celgene Corporation; Contracted Research: CTI BioPharma Corp, Incyte Corporation, Janssen Biotech Inc, Merck, Merus BV, Novartis, Promedior Inc, Roche Laboratories Inc; Data and Safety Monitoring Board: Novartis.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Celgene Corporation and Incyte Corporation.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: July 2019
  Expiration date: July 2020